L9LS

BIOLOGICAL3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Office of Clinical Research Policy and Regulatory Operations NIAID NIH

Conditions

MalariaPlasmodium Falciparum Infection

Phase 1

L9LS MAb in Malian Infants

CompletedNCT06461026

National Institute of Allergy and Infectious Diseases (NIAID)Malaria

Start: 2024-08-19End: 2025-06-27Updated: 2026-09-03

Phase 2

Anti-malaria MAb in Kenyan Children

CompletedNCT05400655

National Institute of Allergy and Infectious Diseases (NIAID)Malaria, Plasmodium Falciparum Infection

Start: 2022-09-14End: 2024-06-02Updated: 2025-10-16

L9LS antimalaria monoclonal antibody for malaria prevention in young infants in western Kenya

Active, not recruitingPACTR202410517100221

Office of Clinical Research Policy and Regulatory Operations NIAID NIHMalaria

Start: 2024-12-02Target: 326Updated: 2026-08-03

Related Papers

Anti-sporozoite monoclonal antibody for malaria prevention: secondary efficacy outcome of a phase 2 randomized trial

Nature Medicine2025-06-035 citations